信立泰(002294.SZ)：信超妥、复立安、恩那罗等药品纳入国家医保目录

Core Viewpoint - Xinlitai (002294.SZ) has announced that its product, Aliskiren Tablets, has been included in the regular catalog of medical insurance under Category B management, reflecting the company's commitment to enhancing drug accessibility and meeting unmet clinical needs in the cardiovascular chronic disease sector [1] Group 1: Product Inclusion in Medical Insurance - Aliskiren Tablets have been included in the medical insurance catalog under Category B management [1] - Other products such as Rolitin (Aliskiren Amlodipine Tablets) and Xinlitin (Benzyl Acid Faglitin Tablets) have previously been negotiated for inclusion in the medical insurance catalog and are still under valid agreements [1] Group 2: Focus on Chronic Disease Management - The company is focusing on the cardiovascular chronic disease field, particularly on Cardio-Renal Metabolic Syndrome (CKM) [1] - A differentiated product portfolio has been established to address various pathogenesis and patient classification characteristics in hypertension, covering the entire treatment needs from primary hypertension without complications to diseases with cardio-renal target organ damage [1] Group 3: Innovation and Market Strategy - Six new chronic disease drugs have been included in the medical insurance catalog through negotiations, demonstrating national support for innovative drugs with high clinical value [1] - The company aims to leverage policy opportunities to actively promote the inclusion of negotiated drugs in hospitals and market coverage, continuously enhancing drug accessibility based on clinical value [1]